TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15448985
Drug: Alendronate (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5-20 mg/day, with over 95% receiving 5 or 10 mg/day)
Study: 1761174
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of metronidazole (500 mg vaginal suppository) before hysterectomy
Study: 7043104
Drug: Weight-reduction treatment
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-reduction treatment program with diet instruction and weekly meetings with a dietitian for 16 months
Study: 27979041
Drug: Wait-and-see approach
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-and-see approach (rate control medication until spontaneous conversion, with possible cardioversion within 48 hours)
Study: 25945079
Drug: Acute magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute magnesium supplementation (300 mg/d for 1 week)
Study: 25945079
Drug: Chronic magnesium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic magnesium supplementation (300 mg/d for 4 weeks)
Study: 19122548
Drug: Butorphanol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (n = 96): intravenous loading dose of 10 microg kg(‐1) butorphanol followed by infusion of 2 microg kg(‐1) h(‐1) butorphanol combined with intravenous PCA set at a bolus of 0.02 mg kg(‐1) morphine
Study: 15352914
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg continuous
Study: 11434941
Drug: Intralipid 10%
Normalized name: Intralipid 10% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 10% (1.5 ml/min)
Study: 9887454
Drug: 5-year therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-year therapy
Study: 8556965
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg p.o. daily
Study: 8556965
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg p.o. bid
Study: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
Normalized name: Auro Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurokeratinate (Auro-Detoxin) administered intramuscularly at slowly rising doses
Study: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
Normalized name: Auro Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurokeratinate (Auro-Detoxin) at 25 mg gold twice weekly
Study: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
Normalized name: Auro Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurokeratinate (Auro-Detoxin) at 65 mg gold once a month
Study: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
Normalized name: Auro Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurokeratinate (Auro-Detoxin) at 50 mg gold every 14 days as maintenance dose
Study: 20573925
Drug: Pharmacotherapy-EBL group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy-EBL group (continuation of vasoactive-drug therapy, propranolol or nadolol, long-term endoscopic band ligation)
Study: 20573925
Drug: Pharmacotherapy-EBL group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy-EBL group
Study: 16807023
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus, one inhalation twice daily for 12 weeks
Study: 16807023
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus plus 20 mg Enoxaparin administered subcutaneously once daily for 12 weeks
Study: 10997957
Drug: ANDRO‐6 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANDRO‐6 (300 mg androstenedione, 150 mg DHEA, 750 mg Tribulus terrestris, 625 mg Chrysin, 300 mg Indole‐3‐carbinol, 540 mg Saw palmetto)
Study: 1735264
Drug: Verapamil, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 120 mg three times daily
Study: 6694008
Drug: Low-pressure spray
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-pressure spray irrigation of corn fields with partially treated wastewater
Study: 6694008
Drug: Workers cleaning
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workers cleaning spray nozzles
Study: 26933301
Drug: DSS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSS and ESS administered together
Study: 17216221
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2 g/day for 3 months
Study: 9339678
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (carbamazepine, phenytoin, phenobarbital, or sodium valproate)
Study: 9339678
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (treatment only after another seizure)
Study: 9339678
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment and delayed treatment
Study: 3856293
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2
Study: 8449431
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg PGE2
Study: 8449431
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg PGE2
Study: 28238742
Drug: Steroids (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (including clobetasol)
Study: 11258331
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of Vazaprostan‐20 into the pulmonary artery
Study: 8059746
Drug: Oral irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigation with automatic toothbrush (n = 16)
Study: 8059746
Drug: Oral irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigation with manual toothbrushing (n = 16)
Study: 3133716
Drug: Trazodone 150
Normalized name: traZODone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 150 mg nocte
Study: 3133716
Drug: Mianserin 30
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 30 mg nocte for 7 days, then 60 mg nocte for 5 weeks
Study: 3133716
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Trazodone and Mianserin)
Study: 15111846
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg once a day for 45 days
Study: 15556053
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (≤125 mg daily)
Study: 1491774
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg single oral administration)
Study: 1491774
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg capsules daily for 5 days)
Study: 3100311
Drug: Aluminium containing
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium containing antacids (1, 4, or 8 tablets, 244 mg aluminium per tablet) taken with citric acid solution
Study: 3100311
Drug: Aluminium containing
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium containing antacids (1, 4, or 8 tablets, 244 mg aluminium per tablet) taken with orange juice
Study: 3100311
Drug: Aluminium containing
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium containing antacids (4 tablets) taken with water
Study: 3100311
Drug: Aluminium containing
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium containing antacids (1, 4, or 8 tablets) taken with water
Study: 3100311
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of aluminium containing antacids
Study: 3100311
Drug: Aluminium containing
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium containing antacids taken with orange juice or citric acid
Study: 26814280
Drug: Daily morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily morphine (n=11)
Study: 22908326
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (SpA patients)
Study: 22908326
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (mAbs)
Study: 22908326
Drug: Etanercept (Anti-TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (Anti-TNF therapy)
Study: 22908326
Drug: Older age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older age and mAb treatment
Study: 20492876
Drug: Intermittent etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intermittent etanercept therapy
Study: 18639771
Drug: Ezetimibe-based therapy
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe-based therapy
Study: 8600096
Drug: AK-2123 (880
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK-2123 (880 mg) with discontinuous accelerated hyperfractionated radiation
Study: 8600096
Drug: AK-2123 (990
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK-2123 (990 mg) with discontinuous accelerated hyperfractionated radiation
Study: 6817123
Drug: Captopril after
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril after diuretic (thiazide) pretreatment
Study: 6817123
Drug: Captopril without
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril without diuretic (thiazide) pretreatment
Study: 30105808
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (couple therapy other than EFT)
Study: 30674586
Drug: Inhaled saline
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled saline
Study: 23758233
Drug: On-demand inhalation
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand inhalation
Study: 23758233
Drug: Fixed-schedule inhalation
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-schedule inhalation
Study: 19249410
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g daily of omega‐3‐acid ethyl esters
Study: 17288648
Drug: Exposure-based and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based and cognitive restructuring therapy
Study: 16279283
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of folic acid, vitamin B6, and vitamin B12
Study: 12390056
Drug: Tocopherol 400
Normalized name: alpha-tocopherol 400 UNT / ubidecarenone 200 MG Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol 400 IU daily
Study: 12390056
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg daily plus tocopherol 400 IU daily
Study: 9836032
Drug: Rocuronium (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.6 mg.kg‐1; n = 20)
Study: 9836032
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg.kg‐1; n = 21)
Study: 6180050
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of human fibroblast-derived (beta) interferon (HulFN-beta) at a total of 1-2 x 10(5) reference units per day, divided into 8-10 drops.
Study: 6180050
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of human fibroblast-derived (beta) interferon (HulFN-beta)
Study: 6180050
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy or placebo containing human serum albumin, with the same administration schedule.
Study: 6180050
Drug: Doses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of interferon lower than 5 x 10(4) units per day
Study: 29362205
Drug: Video with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video with drug risk information
Study: 29362205
Drug: Video without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video without drug risk information
Study: 15860855
Drug: Adjuvant anthracycline-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant anthracycline-based chemotherapy
Study: 12619921
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 2.5 U/day
Study: 12619921
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 1.0 U/day
Study: 8471372
Drug: Diclofenac 150
Normalized name: diclofenac sodium 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 150 mg/24 h
Study: 8471372
Drug: Ketoprofen 200
Normalized name: ketoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 200 mg/24 h
Study: 28589894
Drug: Antenatal expressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal expressing (expressing breastmilk twice per day from 36 weeks' gestation)
Study: 23359491
Drug: Mericitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine 1,000 mg BID plus Peg‐IFNα‐2a/RBV
Study: 9093678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HIT and HSN
Study: 8203844
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg daily for 3 days (multiple-dose administration)
Study: 8203844
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg as a single dose (single-dose administration)
Study: 8203844
Drug: Fleroxacin administered
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin administered in a fed state
Study: 31338868
Drug: Liraglutide (1.2-1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2-1.8 mg/d for 26 weeks)
Study: 28982906
Drug: GA with
Normalized name: Tums with Gas Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA with single-injection thoracic paravertebral block (s-TPVB)
Study: 25028082
Drug: 10-g milk-LNS
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-g milk-LNS
Study: 25028082
Drug: 20-g milk-LNS
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-g milk-LNS
Study: 25028082
Drug: 20-g non-milk-LNS
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-g non-milk-LNS
Study: 25028082
Drug: 40-g milk-LNS
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-g milk-LNS
Study: 25028082
Drug: 40-g non-milk-LNS
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-g non-milk-LNS
Study: 23456732
Drug: ATV400 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV400 (400 mg once daily)
Study: 23456732
Drug: ATV300/r (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV300/r (300 mg ATV plus 100 mg ritonavir once daily)
Study: 20817749
Drug: THC (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (4, 6, and 6 mg, vaporized and inhaled)
Study: 20817749
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of MDMA and THC
Study: 9589229
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of water with 25 g glucose
Study: 9589229
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml of water with 25 g glucose
Study: 9589229
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of water with 25 g sucrose
Study: 9589229
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml of water with 25 g sucrose
Study: 9589229
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of water with 25 g fructose
Study: 9589229
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml of water with 25 g fructose
Study: 2648791
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (group 1)
Study: 27620550
Drug: Lipopolysaccharide (LPS)
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopolysaccharide (LPS) administration at a dose of 2 ng/kg
Study: 24131168
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) administration
Study: 21735655
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol hydrochloride with behavioral modification
Study: 21735655
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy only
Study: 11207994
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation therapy
Study: 19433387
Drug: Up-front zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Up-front zoledronic acid (ZA; 4 mg intravenously every 6 months)
Study: 19433387
Drug: Delayed-start zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months)
Study: 16904446
Drug: Tolterodine extended
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended release (TER) 4 mg daily
Study: 14698800
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg buprenorphine per day
Study: 14698800
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg buprenorphine per day
Study: 7824150
Drug: Low-dose nitroglycerin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nitroglycerin (5-20 micrograms/minute)
Study: 7824150
Drug: High-dose nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nitroglycerin (80-240 micrograms/minute)
Study: 3415015
Drug: N2O (70%)
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N2O (70%) and fentanyl (10 micrograms/kg iv bolus followed by 4 micrograms.kg‐1.h‐1 infusion) with additional warming (humidified respiratory gases, warmed intravenous fluids, and a heating blanket over the legs; n = 5)
Study: 3415015
Drug: N2O (70%)
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N2O (70%) and fentanyl (10 micrograms/kg iv bolus followed by 4 micrograms.kg‐1.h‐1 infusion) with standard temperature management (no special warming measures; n = 10)
Study: 21091898
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g phenacetin (single oral dose)
Study: 18208572
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg capsule of aprepitant
Study: 18208572
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg capsule of aprepitant
Study: 16772708
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 12,000 U twice/month for 6 months
Study: 14634405
Drug: 5 cc
Normalized name: Syringe Unit 35 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 cc saline
Study: 14634405
Drug: 2.5 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 cc 1% lidocaine (bilateral basal injection)
Study: 14634405
Drug: 5 cc
Normalized name: Syringe Unit 35 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 cc 1% lidocaine
Study: 14634405
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc 1% lidocaine
Study: 14634405
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc 1% lidocaine (bilateral basal plus apical injections)
Study: 10952826
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with normal glucose and insulin levels
Study: 30522550
Drug: Propylthiouracil, Jelfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil, Jelfa tablets
Study: 30522550
Drug: Propycil tablets
Normalized name: Propyl Gallate
DrugBank: Propyl Gallate (DB12450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propycil tablets
Study: 23635626
Drug: Combination (Metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (Metoclopramide 10 mg + Ondansetron 4 mg)
Study: 8973669
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (randomized group)
Study: 1434877
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (medical treatment)
Study: 6477250
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection of 2% mepivacaine hydrochloride (with hyaluronidase added in 12 patients)